Beta-Blockers After Myocardial Infarction and Preserved Ejection Fraction
Source : https://pubmed.ncbi.nlm.nih.gov/38587241/
Among patients with acute myocardial infarction who underwent early coronary angiography and had a preserved left ventricular ejection fraction (≥50%), long-term beta-blocker treatment did not lead to a lower risk...
Beta blockers did not lead to a lower cumulative incidence of the secondary endpoints (death from any cause, death from CV causes, MI, hospitalization for atrial fibrillation, and hospitalization for HF).
Causes and Clinical Outcomes of Patients Who Failed Screening for Transcatheter Tricuspid Valve Interventions
Source : https://pubmed.ncbi.nlm.nih.gov/38582312/
Transcatheter tricuspid valve intervention (TTVI) has recently emerged as a promising alternative to surgery for tricuspid regurgitation (TR). However, a significant proportion of patients fail screening for TTVI, and little...
The clinical outcomes of these patients who received optimized medical therapy alone were poor, with a 1-year composite of cardiac death or heart failure readmission of 47.4%.
Semaglutide in Patients With Obesity-Related Heart Failure and Type 2 Diabetes
Source : https://pubmed.ncbi.nlm.nih.gov/38587233/
Among patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide led to larger reductions in heart failure-related symptoms and physical limitations and greater weight loss...
Among patients with obesity-related HF with preserved ejection fraction and type 2 diabetes, semaglutide led to larger reductions in HF-related symptoms and physical limitations and greater weight loss than placebo at 1 year.
The models studied performed better than the measurement of N-terminal pro–brain natriuretic peptide level alone.
Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction
Source : https://pubmed.ncbi.nlm.nih.gov/38591260/
URL: https://www.clinicaltrials.gov; Unique identifier: NCT03496168.
Empagliflozin reduced the risk for first and total HF hospitalization, irrespective of LVEF or congestion or both.